154 related articles for article (PubMed ID: 32075300)
21. Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate.
Swanstrom JA; Henein S; Plante JA; Yount BL; Widman DG; Gallichotte EN; Dean HJ; Osorio JE; Partidos CD; de Silva AM; Baric RS
J Infect Dis; 2018 May; 217(12):1932-1941. PubMed ID: 29800370
[TBL] [Abstract][Full Text] [Related]
22. Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections.
Hertz T; Beatty PR; MacMillen Z; Killingbeck SS; Wang C; Harris E
J Immunol; 2017 May; 198(10):4025-4035. PubMed ID: 28381638
[TBL] [Abstract][Full Text] [Related]
23. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus.
Swanstrom JA; Plante JA; Plante KS; Young EF; McGowan E; Gallichotte EN; Widman DG; Heise MT; de Silva AM; Baric RS
mBio; 2016 Jul; 7(4):. PubMed ID: 27435464
[TBL] [Abstract][Full Text] [Related]
24. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
[TBL] [Abstract][Full Text] [Related]
25. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
[TBL] [Abstract][Full Text] [Related]
26. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
[TBL] [Abstract][Full Text] [Related]
27. Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.
Mareze VA; Borio CS; Bilen MF; Fleith R; Mirazo S; Mansur DS; Arbiza J; Lozano ME; Bruña-Romero O
Appl Microbiol Biotechnol; 2016 Jan; 100(1):125-33. PubMed ID: 26386688
[TBL] [Abstract][Full Text] [Related]
28. Comparative immunogenicity of preparations of yeast-derived dengue oral vaccine candidate.
Bal J; Luong NN; Park J; Song KD; Jang YS; Kim DH
Microb Cell Fact; 2018 Feb; 17(1):24. PubMed ID: 29452594
[TBL] [Abstract][Full Text] [Related]
29. Dissecting the human serum antibody response to secondary dengue virus infections.
Patel B; Longo P; Miley MJ; Montoya M; Harris E; de Silva AM
PLoS Negl Trop Dis; 2017 May; 11(5):e0005554. PubMed ID: 28505154
[TBL] [Abstract][Full Text] [Related]
30. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.
Sukupolvi-Petty S; Austin SK; Purtha WE; Oliphant T; Nybakken GE; Schlesinger JJ; Roehrig JT; Gromowski GD; Barrett AD; Fremont DH; Diamond MS
J Virol; 2007 Dec; 81(23):12816-26. PubMed ID: 17881453
[TBL] [Abstract][Full Text] [Related]
31. Combination of Modified NS1 and NS3 as a Novel Vaccine Strategy against Dengue Virus Infection.
Kao YS; Yu CY; Huang HJ; Tien SM; Wang WY; Yang M; Anderson R; Yeh TM; Lin YS; Wan SW
J Immunol; 2019 Oct; 203(7):1909-1917. PubMed ID: 31451673
[TBL] [Abstract][Full Text] [Related]
32. Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies.
Tripathi L; Mani S; Raut R; Poddar A; Tyagi P; Arora U; de Silva A; Swaminathan S; Khanna N
Front Microbiol; 2015; 6():1005. PubMed ID: 26441930
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II.
Rocha RP; Livonesi MC; Fumagalli MJ; Rodrigues NF; da Costa LC; Dos Santos MC; de Oliveira Rocha ES; Kroon EG; Malaquias LC; Coelho LF
Virus Res; 2014 Aug; 188():122-7. PubMed ID: 24768848
[TBL] [Abstract][Full Text] [Related]
34. An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2.
Tang CT; Li PC; Liu IJ; Liao MY; Chiu CY; Chao DY; Wu HC
PLoS Negl Trop Dis; 2015; 9(7):e0003903. PubMed ID: 26135599
[TBL] [Abstract][Full Text] [Related]
35. Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice.
Coconi-Linares N; Ortega-Dávila E; López-González M; García-Machorro J; García-Cordero J; Steinman RM; Cedillo-Barrón L; Gómez-Lim MA
Vaccine; 2013 May; 31(19):2366-71. PubMed ID: 23499580
[TBL] [Abstract][Full Text] [Related]
36. Homotypic antibodies target novel E glycoprotein domains after natural DENV 3 infection/vaccination.
Munt JE; Henein S; Adams C; Young E; Hou YJ; Conrad H; Zhu D; Dong S; Kose N; Yount B; Meganck RM; Tse LPV; Kuan G; Balmaseda A; Ricciardi MJ; Watkins DI; Crowe JE; Harris E; DeSilva AM; Baric RS
Cell Host Microbe; 2023 Nov; 31(11):1850-1865.e5. PubMed ID: 37909048
[TBL] [Abstract][Full Text] [Related]
37. DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection.
Slon Campos JL; Poggianella M; Marchese S; Mossenta M; Rana J; Arnoldi F; Bestagno M; Burrone OR
PLoS One; 2017; 12(7):e0181734. PubMed ID: 28742857
[TBL] [Abstract][Full Text] [Related]
38. The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice.
Chen HW; Hu HM; Wu SH; Chiang CY; Hsiao YJ; Wu CK; Hsieh CH; Chung HH; Chong P; Leng CH; Pan CH
PLoS One; 2015; 10(12):e0145717. PubMed ID: 26714037
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
[TBL] [Abstract][Full Text] [Related]
40. Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in Escherichia coli.
Yang J; Zhang J; Chen W; Hu Z; Zhu J; Fang X; Yuan W; Li M; Hu X; Tan Y; Hu F; Rao X
Can J Microbiol; 2012 Apr; 58(4):369-80. PubMed ID: 22420529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
